EQL Pharma AB (OSTO:EQL) Interest Expense: kr-30.5 Mil (TTM As of Mar. 2026)


OSTO:EQL EQL Pharma AB OSTO:EQL
42 GF Score
Price kr23.85
! 4 Warning Signs
View Full Analysis

What is EQL Pharma AB Interest Expense?

EQL Pharma AB OSTO:EQL +3.02% 42 Interest Expense is kr-30.5 Mil as of Mar. 2026. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. EQL Pharma AB's interest expense for the three months ended in Mar. 2026 was kr -7.4 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr-30.5 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. EQL Pharma AB's Operating Income for the three months ended in Mar. 2026 was kr 5.1 Mil. EQL Pharma AB's Interest Expense for the three months ended in Mar. 2026 was kr -7.4 Mil. EQL Pharma AB's Interest Coverage for the quarter that ended in Mar. 2026 was 0.69. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

EQL Pharma AB  (OSTO:EQL) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

EQL Pharma AB's Interest Expense for the three months ended in Mar. 2026 was kr-7.4 Mil. Its Operating Income for the three months ended in Mar. 2026 was kr5.1 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was kr345.2 Mil.

EQL Pharma AB's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*5.114/-7.387
=0.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

EQL Pharma AB Interest Expense Historical Data

* Premium members only.

The historical data trend for EQL Pharma AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EQL Pharma AB Interest Expense Chart

EQL Pharma AB Annual Data
Trend Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.87 -2.37 -5.73 -13.02 -30.49

EQL Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.46 -8.08 -7.82 -7.20 -7.39
OSTO:EQL
42GF Score
EQL Pharma AB OSTO:EQL
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EQL Pharma AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-30.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of kr-30.5 Mil mean?
EQL Pharma AB (OSTO:EQL) has a Interest Expense of kr-30.5 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on EQL Pharma AB and its competitors.
Is EQL Pharma AB's Interest Expense too high?
EQL Pharma AB's current Interest Expense is kr-30.5 Mil. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's Interest Expense compare to ZTS and UTHR?
EQL Pharma AB's Interest Expense of kr-30.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on EQL Pharma AB and its competitors. EQL Pharma AB's current Interest Expense is kr-30.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current Interest Expense of kr-30.5 Mil. The current Interest Expense is kr-30.5 Mil. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current Interest Expense is kr-30.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EQL Pharma AB Business Description

Other Exchanges 7JK:Germany
Address Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score

Get the complete analysis for OSTO:EQL

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr23.85
Price